Literature DB >> 20043081

Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells.

Jing Peng1, V Craig Jordan.   

Abstract

Endocrine therapies targeting estrogen action are pivotal for the prevention and treatment of ER-positive breast cancers. Previous studies sought to recreate hormone responsiveness by the stable expression of ERalpha in the ER-negative MDA-MB-231 breast cancer cells. Paradoxically, estrogen inhibits breast cancer cell growth when an exogenous ERalpha is expressed. In this study, we have built on previous studies by developing a Tet-off adenoviral system to express ERalpha in the ER-negative SKBr3 breast cancer cells that over-express both EGFR and HER2. This system efficiently delivers ERalpha and the expression level of ERalpha is controlled by doxycycline in a concentration-dependent manner. The growth of SKBr3 was inhibited by ERalpha expression and further inhibited in the presence of 1 nM 17beta-estradiol. SKBr3 cells were arrested at G0/G1 cell cycle upon ERalpha expression, which corresponded to an increase of p21Cip1/Waf1, hypo-phosphorylation of pRb and decrease of E2F1. Estrogen also reduced EGFR and HER2 expression in SKBr3 cells after ERalpha was expressed. Given that estrogen-induced increase of p21Cip1/Waf1 and decrease of E2F1 was also observed in MDA-MB-231 cells stably transfected with ERalpha, our results suggest that a common pathway might be shared by different breast cancer cell lines whose growth is suppressed by ectopic ERalpha and estrogen.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043081      PMCID: PMC2842990     

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  30 in total

1.  Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.

Authors:  R X Song; G Mor; F Naftolin; R A McPherson; J Song; Z Zhang; W Yue; J Wang; R J Santen
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

2.  Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.

Authors:  C S Murphy; J J Pink; V C Jordan
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

Review 3.  A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Recent Results Cancer Res       Date:  1993

4.  Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor.

Authors:  S Y Jiang; V C Jordan
Journal:  J Natl Cancer Inst       Date:  1992-04-15       Impact factor: 13.506

5.  E2F-1: a proliferative marker of breast neoplasia.

Authors:  S Y Zhang; S C Liu; L F Al-Saleem; D Holloran; J Babb; X Guo; A J Klein-Szanto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-04       Impact factor: 4.254

6.  Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.

Authors:  K Yao; E S Lee; D J Bentrem; G England; J I Schafer; R M O'Regan; V C Jordan
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.

Authors:  J J Pink; M M Bilimoria; J Assikis; V C Jordan
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

8.  E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide.

Authors:  Sehwan Han; Kyeongmee Park; Byung-Noe Bae; Ki Hwan Kim; Hong-Joo Kim; Young-Duck Kim; Hong-Yong Kim
Journal:  Breast Cancer Res Treat       Date:  2003-11       Impact factor: 4.872

Review 9.  Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines.

Authors:  A S Levenson; V C Jordan
Journal:  J Steroid Biochem Mol Biol       Date:  1994-12       Impact factor: 4.292

10.  Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.

Authors:  L D Read; D Keith; D J Slamon; B S Katzenellenbogen
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

View more
  4 in total

1.  Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.

Authors:  Surojeet Sengupta; Michael C Biarnes; Robert Clarke; V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2015-02-27       Impact factor: 4.872

2.  Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).

Authors:  Reyhaan A Chaudhri; Rene Olivares-Navarrete; Natalia Cuenca; Agreen Hadadi; Barbara D Boyan; Zvi Schwartz
Journal:  J Biol Chem       Date:  2012-01-13       Impact factor: 5.157

3.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines.

Authors:  Kristina Subik; Jin-Feng Lee; Laurie Baxter; Tamera Strzepek; Dawn Costello; Patti Crowley; Lianping Xing; Mien-Chie Hung; Thomas Bonfiglio; David G Hicks; Ping Tang
Journal:  Breast Cancer (Auckl)       Date:  2010-05-20

4.  Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line.

Authors:  Junaid A Khan; Catherine Bellance; Anne Guiochon-Mantel; Marc Lombès; Hugues Loosfelt
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.